A preview of this full-text is provided by SAGE Publications Inc.
Content available from Integrative Cancer Therapies
This content is subject to copyright.
164
laser ablation, electrofulguration, and cold coagulation)
and excisional (loop electrosurgical excision procedure
[LEEP], cold-knife conization, laser conization, and elec-
trosurgical needle conization) treatments may be imple-
mented in biopsy-confirmed CIN II, III lesions; however,
only excisional therapies are acceptable treatment options
with unsatisfactory colposcopy.2 In either case, the entire
transformation zone must be removed for the treatment
to be effective.2-5
In consideration of appropriate treatment modalities,
a satisfactory colposcopy indicates both excisional and
ablative procedures are acceptable. Previously, LEEP was
preferable to cold-knife conization because it does not
require general anesthesia and the excised tissue can be
used for diagnostic as well as therapeutic purposes. Also,
it was believed in the early 1990’s that LEEP did not have
the risks on future pregnancies that were linked to cold-
knife conization, including preterm labor, low birth-
weight infants, and cesarean section.3 Emergent research
has demonstrated an association between LEEP and
increased risk of preterm birth, premature rupture of
membranes associated with the increased depth of tissue
removed during the procedure,4 overall increased risk of
preterm delivery, and low birth weight infants.6 The
increased risk of spontaneous preterm birth has been
linked to a short cervical length independent of biological
or postprocedure nature.7 This implies a causal relation-
ship between the degree of invasiveness of a cervical
procedure and the risk of pregnancy complications. Since
The purpose of women’s annual Papanicolaou (Pap)
testing is to detect cytological abnormalities of the
cervix, which can indicate cervical disease. This
screening test has helped in early detection of cervical
dysplasia, which is associated with the sexually transmit-
ted human papillomavirus (HPV) infection. Exposure
to HPV is directly linked to the development of cervical
dysplasia and found in up to 95% of all cervical squa-
mous cell cancers.1 In 2006, the American Society for
Colposcopy and Cervical Pathology (ASCCP) issued an
updated consensus for the management and treatment of
cervical cytological abnormalities. These guidelines act as
the professional standard of care for management of
women with cervical intraepithelial neoplasia (CIN) or
adenocarcinoma in situ (AIS).2 Histological classification
of CIN is a 2-tiered system based on severity: CIN 1 indi-
cates low-grade lesions, while CIN II, III indicate high-
grade lesions.2 The severity of histological diagnosis, used
in combination with colposcopic findings, acts as the
standard for determining clinical management. While
spontaneous regression rates are high with CIN 1, ASCCP
recommends treatment to reduce incidence and mortality
from invasive cervical cancer in cases of CIN II, III.2
With a satisfactory colposcopy, both ablative (cryotherapy,
Background. This report describes a case of a woman with
progressive and recurrent cervical dysplasia 4 years after
cervical conization for severe dysplasia. Patient and methods.
A 20-year-old female was referred for colposcopy and biopsy
following results of moderate to severe atypia of cervical cells
on her Papanicolaou (Pap) test. Her colposcopy was satisfac-
tory and her biopsy revealed cervical intraepithelial neoplasia
(CIN) II, III. She refused the conventional recommendation
of loop electrosurgical excision procedure (LEEP) and, as an
alternative, elected to receive escharotic treatment at a fre-
quency of 2 treatments per week for 5 weeks. In addition to
the escharotic treatment she followed an oral vitamin and
botanical protocol. She was followed for 5 years. Results. The
patient’s 4-month and 10-month follow-up Pap smears
revealed negative cervical cytology for intraepithelial lesion
or malignancy. Her 10-month colposcopy was satisfactory
and no lesions were noted on the colposcopic exam. Liquid
based Pap results continued to remain normal for 5 years
after the initiation of treatment. Discussion. Escharotic treat-
ment of high-grade cervical neoplasias with satisfactory
colposcopy holds promise as an effective and low-risk alter-
native therapy to LEEP and other excisional procedures.
Keywords: cervical dysplasia; complementary and alterna-
tive medicine; herbs; botanical medicine; escharotic; LEEP
alternative
From the Natural Health Center, National College of Natural Medicine,
Portland, Oregon. Address correspondence to: Heather Zwickey, PhD,
Natural Health Center, National College of Natural Medicine, 2220
SW First Ave, Portland, OR 97210; e-mail: hzwickey@ncnm.edu.
Integrative Cancer Therapies
Volume 8 Number 2
June 2009 164-167
© 2009 The Author(s)
10.1177/1534735409335504
http://ict.sagepub.com
An Alternative Treatment for Cervical
Intraepithelial Neoplasia II, III
Summer Swanick, BS, Kimberly Windstar-Hamlin, MEd, ND, and Heather Zwickey, PhD
Alternative Treatment for Cervical Intraepithelial Neoplasia / Swanick et al 165
the ASCCP considers both ablative and excisional proce-
dures to have similar efficacy in eliminating CIN and
reducing the risk of progression to invasive cervical can-
cer, more research on ablative options and their potential
risks and benefits is warranted, especially for women in
their reproductive years.
Escharotic treatment is an ablative therapy that has
been used to treat cervical dysplasia in women with a
satisfactory colposcopy who have refused the recom-
mended conventional treatments. An escharotic agent is
a substance that is corrosive to flesh and burns on physi-
cal contact causing sloughing of the tissues. The resultant
scab is known as an eschar. Escharotic treatment involves
the application of a caustic paste to superficial tissues to
obliterate neoplastic growth and to allow healthy growth
to occur. When performed by a licensed and appropri-
ately trained health care professional, this procedure is
believed to have positive outcomes and is accompanied by
an oral protocol of immune-enhancing and anticarcino-
genic supplements. The criticism of such treatments in
medical literature generally addresses cases where indi-
vidual patients refused the medical standard of care treat-
ment in favor of self-prescribed, unsupervised treatment
with an escharotic concoction purchased by the patient
through the Internet.8,9
This report provides evidence for the efficacy of escha-
rotic treatment for CIN II, III in a case of recurrent, high-
grade neoplasia following conventional cervical conization.
The strength of this case emphasizes the need for clinical
research to explore the long-term effectiveness and poten-
tial risks of escharotic treatment for cervical dysplasia.
Currently, there is no information in medical literature on
long-term safety or complications that can be expected
from this ablative procedure.
Patient and Methods
A 20-year-old Caucasian female was referred to our
naturopathic clinic for colposcopy and biopsy after abnor-
mal Pap smear results from her conventional physician in
October 2002 revealed CIN II, III (moderate to severe
dysplasia), high-grade squamous intraepithelial lesions
(HSIL) with endocervical material present. She had a his-
tory of a cone biopsy for severe dysplasia dating back
4 years prior to her present visit, as well as present genital
warts and vulvar HPV lesions with pruritis. She had sev-
eral risk factors for cervical dysplasia, including early age
of first intercourse, >3 new sexual partners in the past
12 months and 15 total partners, and a 6-year history of
tobacco use. She had a history of 1 pregnancy, 1 abortion,
and 0 live births. She had a family history of breast can-
cer, lymphoma, cervical cancer, and systemic lupus ery-
thematous. Her vitals were within normal limits and
remained so throughout her treatment at our clinic. Her
colposcopy revealed a satisfactory exam with endocervical
speculum, which allowed her to be a candidate for escha-
rotic treatment. White epithelium 1-3+, fine mosaicism,
course mosaicism, and course punctuation were noted on
the colposcopic exam. The cervical biopsy revealed benign
material and mild acute inflammatory processes in the
endocervical canal (ECC), though moderate to focal
severe dysplasia (CIN II, III) was found on the cervical
biopsies with extension into the glands.
We recommended that she have a LEEP for her CIN
II, III as per ASCCP guidelines for standard of care at the
time of assessment. The patient refused the recom-
mended surgical procedure. She was unwilling to have
another surgical procedure after her experience with the
cone biopsy and signed a refusal of medical treatment
form. The patient was given information on the escha-
rotic treatment as an alternative, and opted to begin treat-
ment the following month. In addition to the escharotic
treatment, she was given the oral immune supporting and
anticarcinogenic HPV protocol (see Table 1).
The escharotic treatment protocol used in this case
study is a 4-step process, which takes a total of approxi-
mately 20 minutes per visit, 2 visits per week for 5 weeks.
(See Table 2)
Results
The patient received a total of 10 escharotic treat-
ments at a frequency of 2 treatments per week, each
treatment taking 20 minutes. Adverse symptoms reported
included cramping, burning and stinging pain, and spot-
ting. All were temporary and self-resolving symptoms that
may occur with this treatment. One month following the
completion of her escharotic treatments she returned to
clinic for a follow-up. A liquid based Pap was collected
and testing for high risk HPV was performed. Pap results
were satisfactory for interpretation and showed ASC-US.
HPV was suspected, however, she was negative for high-
risk types of HPV. Two small areas of white epithelium 1+
and fine mosaicism were noted on satisfactory colposcopic
Table 1. Oral HPV Protocol
Supplement Dosage
Folic acid10,11 10 mg per day
Vitamin C12 6 g per day
Beta carotene, natural mixed carotenoids13,14 150 000 IU per day
Green tea extract15,16 500 mg per day
Indole-3-carbinol17,18a 200 mg per day
Antiviral HPV tinctureb60 drops 3 times per day
a Based on emergent research, the current protocol replaces indole-3-carbinol
with diindolylmethane (DIM) 300mg.19
b 2 parts echinacea, 2 parts hypericum, 1 part mahonia, 1 part lomatium, 1 part
thuja, and 1 part thymus.
166 Integrative Cancer Therapies / Vol. 8, No. 2, June 2009
examination, and no biopsies were taken. The patient was
instructed to continue all of her oral supplement treat-
ments and return to the office in 3 months for a colpos-
copy for conservative evaluation of response to escharotic
treatment and a repeat Pap in 4 to 6 months.
In 3 months the patient returned for her follow-up
colposcopy. The colposcopy was satisfactory, revealing
resolution of the fine mosaicism and only 1 area of white
epithelium 1+, demonstrating a positive response to the
treatment. The patient was instructed to continue her
oral protocol supplements and return to our clinic in
2 months for a follow-up Pap.
In 4 months the patient returned for her follow-up
Pap and annual exam. She continued to take her supple-
ments. The colposcopy was satisfactory, and a single
locale of white epithelium 1+, demonstrating a progres-
sive decrease in area since the last visit, was observed on
the colposcopic visual exam. Her annual exam was
performed and a liquid Pap was collected. The results
from the liquid based Pap showed cervical cytology nega-
tive for intraepithelial lesion or malignancy. The patient
was recommended to return to our clinic for a repeat Pap
in 4 to 6 months.
In 10 months the patient returned for her follow-up
Pap. She continued to take her oral supplements and was
feeling well. Her colposcopy was satisfactory and no
lesions were noted on the colposcopic exam. The repeat
Pap test was performed and the results from the liquid-
based Pap revealed negative cervical cytology for intraepi-
thelial lesion or malignancy. The patient was to return to
the clinic in 1 year for her Pap and annual exam.
The patient returned to the clinic for her annual Pap
smear 5 years after her initial visit. Her liquid based Pap
results were normal.
Discussion
The current recommended guidelines for treatment of
CIN II, III as recommended by the ASCCP, especially
considering the risk factors present in this case, support
LEEP. However, potential long-term consequences of
LEEP are emerging in medical literature that strongly
support the need for women of childbearing age with high
grade cervical dysplasia and a satisfactory colposcopy with
negative endocervical curettage to consider ablative ther-
apies. Escharotic treatment is 1 potential alternative
available to these patients.
This case study of a 20-year-old woman with CIN II,
III who refused the LEEP therapy showed complete
remission of cervical dysplasia with escharotic trea-
tment and immune-boosting and anticarcinogenic oral
nutritional and botanical supplements. She showed
no sign of recurrence in either her follow-up Pap smears
or colposcopic examinations. Results of her treatment
were complete remission of evidence for her cervical
dysplasia. The patient remained negative for CIN on
follow-up colposcopy and Pap for 5 years after her initial
visit.
The major drawbacks of escharotic treatment include
the patient time burden of 2 treatments per week for 5
consecutive weeks and the physical discomfort of the
escharotic process during treatments such as minor and
temporary cramping, burning, stinging, and spotting that
may occur. However, the success of this case strongly
supports the need for further investigation into the effi-
cacy and potential long-term risks and side effects of
escharotic treatment for all grades of cervical dysplasia
through comparison studies to other known effective
clinical treatments.
Table 2. Escharotic Treatment Protocol
Step Justification
1. Apply bromelain powder to the cervix. Add light source to the bro-
melain application to increase the temperature and activate the
enzymatic action. Wait for 15 minutes.
Bromelain is a substance derived from the stems and fruit of pineapples
and is composed primarily of proteolytic enzymes. Bromelain has
known antiedematous, anticoagulant, and antimetastatic properties.
It has been used to facilitate soft-tissue wound healing and is being
explored for its ability to enzymatically digest burn eschar and effec-
tively clean the wound areas following second and third degree
burns.20,21,22
2. Remove bromelain powder after 15 minutes with a cotton swab
saturated with Calendula officianalis succus.
Calendula is known for its anti-inflammatory and demulcent properties.23
It is applied to sooth the tissues and decrease reactionary inflammation.
3. Apply escharotic preparation of ¼ tsp zinc chloride mixed with ¾
tsp of sanguinaria tincture to the cervix. Leave on for 1 minute,
then removed with the Calendula succus.
This is the core of the escharotic treatment. Saguinaria candensis has
antioxidant, antimicrobial, antifungal, antiangiogenic, anticancer,
irritant, and escharotic effects.24-26
4. Complete escharotic treatment by inserting 2 vag pack supposito-
ries into the vagina, against the surface of the cervix. The contents
of the suppositories include anhydrous magnesium sulfate, glycerin
complex, hydrastis tincture, thuja oil, tea tree oil, bitter orange oil,
vitamin A (as palmitate) 100 000 IU, ferric sulfate, and ferrous
sulfate in polybase.
This combination of herbs and vitamins has antimicrobial action, specifi-
cally against the human papillomavirus (HPV) and its local infection of
the cervical tissues.27,28
Alternative Treatment for Cervical Intraepithelial Neoplasia / Swanick et al 167
References
1. Sedlacek T. Advances in the diagnosis and treatment of
human papilomavirus infections. Clin Obstet Gynecol. 1999;
42:206-220.
2. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkins EJ,
Solomon D. 2006 consensus guidelines for the management of
women with cervical intraepithelial neoplasia or adenocarci-
noma in situ. J Low Genit Tract Dis. 2007;11:223-239.
3. Cox JT. Management of cervical intraepithelial neoplasia.
Lancet. 1999;353:857-859.
4. Sadler L, Saftlas A. Is it safe to perform LEEP on a patient before
she gets pregnant? Contemp Ob Gyn. 2006; 51(9), 56-64.
5. Spitzer M, Apgar BS, Brotzman GL. Management of histo-
logical abnormalities of the cervix. Am Fam Physician. 2006;
73:105-112.
6. Samson SA, Bentley JR, Fahey TJ, McKay DJ, Gill GH. The
effect of loop electrosurgical procedure on future pregnancy
outcome. Obstet Gynecol. 2005;105:325-332.
7. Crane JMG, Delaney T, Hutchens D. Transvaginal ultrasonogra-
phy in the prediction of preterm birth after treatment for cervical
intraepithelial neoplasia. Obstet Gynecol. 2006;107: 37-44.
8. McDaniel S, Goldman GD. Consequences of using escharotic
agents as primary treatment for nonmelanoma skin cancer.
Arch Dermatol. 2002;138:1593-1596.
9. Elston DM. Escharotic agents, Fred Mohs, and Harry Hoxsey.
J Am Acad Dermatol. 2005;53:523-525.
10. Piyathilake CJ, Henao OL, Macaluso M, et al. Folate is associ-
ated with the natural history of high-risk human papillomavi-
ruses. Cancer Res. 2004;64:8788-8793.
11. Piyathilake CJ, Macaluso M, Brill I, Heimburger DC,
Partridge EE. Lower red blood cell folate enhances the HPV-
16-associated risk of cervical intraepithelial neoplasia. Nutrition.
2007;23:203-210.
12. Ho GY, Palan PR, Basu J, et al. Viral characteristics of human
papillomavirus infection and antioxidant levels as risk factors
for cervical dysplasia. Int J Cancer. 1998;78:594-599.
13. Giuliano AR, Papenfuss M, Nour M, Cangield LM, Schneider
A, Hatch K. Antioxidant nutrients: associations with persistent
human papillomavirus infection. Cancer Epidemiol Biomarkers
Prev. 1997;6:917-923.
14. Palan PR, Goldberg GL, Basu J, Runowicz CD, Romney SL.
Lipid-soluble antioxidants: beta-carotene and alpha-tocopharol
levels in breast and gynecologic cancers. Gynecol Oncol. 1994;
55:72-77.
15. Ahn WS, Yoo J, Huh SW, et al. Protective effects of green tea
extracts (polyphenon E and ECGC) on human cervical lesions.
Eur J Cancer Prev. 2003;12:383-390.
16. Zhang Q, Tang X, Lu Q, Zhang Z, Rao J, Le AD. Green tea
extract and (-)-epigallocatechin-3-gallate inhibit hypoxia-and
erum-induced HIF-1 alpha protein accumulation and VEGF
expression in human cervical carcinoma and hepatoma cells.
Mol Cancer Ther. 2006;5:1227-1238.
17. Auborn KJ. Can intole-3-carbinol-induced change in cervical
intraepithelial neoplasia be extrapolated to other food compo-
nents? J Nutr. 2006;136:2676S-2678S.
18. Bell MC, Crowley-Nowick P, Bradlow HL, et al. Placebo-
controlled trial of indole-3-carbinol in the treatment of CIN.
Gynecol Oncol. 2000;78:123-129.
19. Chen DZ, Qi M, Auborn KJ, Carter TH. Indole-3-carbinol and
diindolylmethane induced apoptosis of human cervical cancer
cells and in nurine HPV16-transgenic preneoplastic cervical
epithelium. J Nutr. 2001;131:3294-3302.
20. Hestermann EV, Brown M. Agonist and chemopreventative
ligands induce differential transcriptional cofactor recruitment
by aryl hydrocarbon receptor. Mol Cell Biol. 2003;23:7920-
7925.
21. Orsini RA. Bromelain. Plast Reconstr Surg. 2006;118:1640-1644.
22. Maurer HR. Bromelain: biochemistry, pharmacology, and
medicinal use. Cell Mol Life Sci. 2001;58:1234-1245.
23. Della Loggia R, Tubaro A, Sosa S, Becker H, Saar S, Isaac O.
The role of triterpenoids in the topical anti-inflammatory activity
of Callendula officinalis flowers. Planta Med. 1994;60:516-520.
24. Jellinek N, Maloney ME. Escharotic and other botanical agents
for the treatment of skin cancer: A review. J Am Acad Dermatol.
2005;53:487-495.
25. Eun J, Koh GY. Supression of angiogenesis by the plant alka-
loid, sanguinarine. Biochem Biophys Res Commun. 2004;317:
618-624.
26. Ahmad N, Gupta S, Husain MM, Heiskanen KM, Muktar H.
Differential antiproliferative and apoptotic response of sangui-
narine for cancer cells versus normal cells. Clin Cancer Res.
2000;6:1524-1528.
27. Millar BC, Moore JE. Successful topical treatment of hand
wards in a paediatric patient with tea tree oil (Melaleuca
alternifolia). Complement Ther Clin Pract. 2008;14:225-227.
28. Graham V, Surwit ES, Weiner S, Meyskens FL. Phase II trial of
β- all-trans-retinoic acid for cervical intraepithelial neoplasia
delivered via a collagen sponge and cervical cap. West J Med.
1986;145:192-195.
For reprints and permissions queries, please visit SAGE’s Web site at http://www.sagepub.com/journalsPermissions.nav.
Content uploaded by Kimberly Windstar
Author content
All content in this area was uploaded by Kimberly Windstar on Nov 27, 2014
Content may be subject to copyright.